During the past decade, The First Affiliated Hospital, Zhejiang University conducted 544 clinical trials. In the 10-year time frame, 544 clinical trials started and 57 clinical trials were completed, i.e. on average, 10.5% percent of trials that started reached the finish line to date. In the past 5 years, 364 clinical trials started and 45 clinical trials were completed. i.e. 12.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The First Affiliated Hospital, Zhejiang University" #1 sponsor was "Zhejiang University" with 93 trials, followed by "First Affiliated Hospital of Zhejiang University" with 77 trials sponsored, "BeiGene" with 23 trials sponsored, "Janssen Research & Development, LLC" with 20 trials sponsored and "Hoffmann-La Roche" with 20 trials sponsored. Other sponsors include 390 different institutions and companies that sponsored additional 202 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The First Affiliated Hospital, Zhejiang University" #1 collaborator was "Yake Biotechnology Ltd." with 27 trials as a collaborator, "First Affiliated Hospital of Zhejiang University" with 14 trials as a collaborator, "First Affiliated Hospital of Wenzhou Medical University" with 9 trials as a collaborator, "LinkDoc Technology (Beijing) Co. Ltd." with 9 trials as a collaborator and "Zhejiang University" with 8 trials as a collaborator. Other collaborators include 587 different institutions and companies that were collaborators in the rest 366 trials.

According to Clinical.Site data, the most researched conditions in "The First Affiliated Hospital, Zhejiang University" are "Non-small Cell Lung Cancer" (23 trials), "Multiple Myeloma" (20 trials), "Hepatocellular Carcinoma" (18 trials), "Advanced Solid Tumor" (10 trials) and "Solid Tumor" (10 trials). Many other conditions were trialed in "The First Affiliated Hospital, Zhejiang University" in a lesser frequency.

Most popular intervention types in "The First Affiliated Hospital, Zhejiang University" are "Drug" (470 trials), "Biological" (62 trials), "Procedure" (41 trials), "Other" (33 trials) and "Device" (28 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (76 trials), "Cisplatin" (15 trials), "Tislelizumab" (15 trials), "Cyclophosphamide" (13 trials) and "placebo" (13 trials). Other intervention names were less common.

The vast majority of trials in "The First Affiliated Hospital, Zhejiang University" are 597 trials for "All" genders, 14 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are 329 active trials in "The First Affiliated Hospital, Zhejiang University". 22 are not yet recruiting, 215 are recruiting, 86 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 164 completed trials in The First Affiliated Hospital, Zhejiang University, 3 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in The First Affiliated Hospital, Zhejiang University, 131 "Phase 1" clinical trials were conducted, 198 "Phase 2" clinical trials and 174 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 58 trials that are defined as “Not Applicable".